U. Shukla

Methods to evaluate and improve the injection site tolerability of intravenous formulations prior to first-in-human testing.

A. De Smedt, L. Lammens, G. Eichenbaum, 2013, Journal of pharmacological and toxicological methods.

Vascular Effects of RWJ‐676070, a Selective Combined V1a/V2 Vasopressin Receptor Antagonist

M. Burnier, M. Maillard, B. Vogt, 2009, Clinical pharmacology and therapeutics.

Role of mixed ion channel effects in the cardiovascular safety assessment of the novel anti‐MRSA fluoroquinolone JNJ‐Q2

Hua-rong Lu, J. Rohrbacher, D. Gallacher, 2012, British journal of pharmacology.

Previously treated recurrent or advanced endometrial cancer in England: A real-world observational analysis.

C. Knott, U. Shukla, K. Heffernan, 2022, Gynecologic oncology.

Methods to evaluate and improve the injection site tolerability of intravenous formulations prior to first-in-human testing.

L. Lammens, J. Zhou, A. Loószová, 2013, Journal of pharmacological and toxicological methods.